Phase 2 Study of ONC201 in Neuroendocrine Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03034200|
Recruitment Status : Recruiting
First Posted : January 27, 2017
Last Update Posted : July 31, 2019
The purpose of this study is to learn if a new drug, ONC201 can make tumors become smaller or go away completely. Investigators also want to learn if ONC201 can prevent new deposits of cancer from appearing in new places in participants (metastases). A phase 2 study of ONC201 in PC-PG (pheochromocytoma-paraganglioma) and other neuroendocrine tumors will determine whether inhibition of DRD2 (a member of the dopamine receptor family) is safe in neuroendocrine cancers including PC-PG.
ONC201 is an investigational (experimental) agent and has a favorable safety profile in phase 1 and early phase 2 clinical trials in advanced cancers. This study design has been chosen to see whether ONC201 is associated with reduction of anti-hypertension medications, safety and significant efficacy against neuroendocrine tumors, especially PC-PG.
|Condition or disease||Intervention/treatment||Phase|
|Recurrent Neuroendocrine Tumor Metastatic Neuroendocrine Tumor||Drug: ONC201||Phase 2|
Primary Objective To demonstrate objective responses using MRI or CT, positron emission tomography - computerized tomography (PET-CT) and/or PET-MRI imaging. The same CT or MRI imaging to assess disease burden at study entry will be compared at week 6 and 3 months. Patients without progression at 3 months will continue treatment and have imaging at 6, 9 and 12 months after study entry. Metabolic response will be compared with study entry PET-CT or PET-MRI and scans at 6 weeks, 3 months and 12 months.
Secondary Objectives Progression - free Survival: This will be calculated according to Response Evaluation Criteria In Solid Tumors (RECIST) or Response Assessment in Neuro-Oncology (RANO) and /or development of new disease
Overall survival: Overall survival will be determined by email or telephone contact.
PG-PG (only): to determine efficacy of ONC201 by reduction in dose of anti-hypertensive medications.
Study Design: Phase 2 open-label fixed dose study Metastatic neuroendocrine tumors including PC-PG are rare diseases. This study design has been chosen to see whether ONC201 is associated with reduction of anti-hypertension medications, safety and significant efficacy against neuroendocrine tumors, especially PC-PG.
The recommended phase II dose as flat every 3 week dosing of 625mg orally every 3 weeks will be used. The same imaging at study entry will be used at subsequent time points (CT or MRI for week 6 and 3, 6, 9, and 12 months; PET-CT or PET-MRI will be at 6 weeks 3 months and 12 months. Imaging modality choice will be influenced by the quality of prior scans of the subject and will be ordered so clinical comparison is possible.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase 2 Study of ONC201 in Neuroendocrine Tumors|
|Actual Study Start Date :||August 2, 2017|
|Estimated Primary Completion Date :||January 2020|
|Estimated Study Completion Date :||January 2020|
625mg by mouth weekly for up to 1 year
625mg ONC201 will be given weekly for up to one year or until progression.
- Tumor response according to RECIST Criteria [ Time Frame: Up to 1 Year ]
Complete Response (CR) Disappearance or fibrosis of all target lesions. Any pathologic lymph nodes must have reduction in short axis to <10mm and standardized uptake value (SUV) is <4.
Partial Response (PR) At least 30% decrease in sum of longest diameters of target lesions (compared to initial on study baseline) and any decrease in SUV in Fludeoxyglucose 18F (18FDG) imaging Stable disease (SD) 0-29% decrease in sum of longest diameters of target lesions (compared to initial on study baseline) or 0-19% increase in sum of longest diameters of target lesions (compared to initial on study baseline). SUV may increase or decrease Progressive disease 20% or more increase of sum of longest diameters of target lesions (compared to initial on study baseline). The sum must also be at an increase of at least 5mm or one or more new lesions that are considered metastatic disease
- Average duration of lack of progression: Clinical response [ Time Frame: Up to 1 Year ]Average time from beginning of treatment to progression, death, or one year, whichever comes first. An underlying clinical benefit rate of 25% would indicate that ONC201 has a therapeutic effect, whereas an underlying rate <5% would indicate a lack of activity
- Overall survival [ Time Frame: Up to 1 Year ]time from beginning of treatment until death, or one year, whichever comes first.
- Average change in anti-hypertensive medication [ Time Frame: from beginning of treatment to 3 months ]to achieve this secondary endpoint of anti-hypertensive medication reduction in PC-PG subjects (N=12) data at 3 months will be required. An underlying clinical benefit rate of 25% would indicate that ONC201 has a therapeutic effect, whereas an underlying rate <5% would indicate a lack of activity
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03034200
|Contact: Peter M Anderson, MD, PhDemail@example.com|
|Contact: Stacey Zahler, DOfirstname.lastname@example.org|
|United States, Ohio|
|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center||Recruiting|
|Cleveland, Ohio, United States, 44195|
|Contact: Peter M Anderson, MD, PhD 216-445-4007 email@example.com|
|Principal Investigator: Peter M Anderson, MD, PhD|
|Principal Investigator:||Peter M Anderson, MD, PhD||Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center|